Fibrocell Science Inc (FCSC)

[scmfinance]

In comparing the Rodman & Renshaw analysis from October 2011 with their report in April of 2011, I found it interesting that they increased their valuation from $3.00/share to $3.50/share. The increase in valuation is also based upon an increased fully diluted share count of 105MM versus 157MM, respectively.

Also, in reviewing the report from April 2011, revenues were forecast at $17M for 2012 and $40M for 2013. These projections were based upon a cost for the procedure of $3,000 which would put their projections around 5,600 procedures for 2012. (Given the discount being offered by FCSC for the procedure, the revenue probably will not hit that forecast unless the number of procedures goes up.) This is 10X what Dew expects.

Oh, and that $17M figure is nearly 3.5X what Botox earned in its first year of sales ($5M).